All In Biotech

Drug Trial Radar · NCT02302456

Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery

Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,079 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,079

Actual

Start

Feb 2015

Primary completion

Jan 2017

Study completion Apr 2017

Sponsor

Lead sponsor
University Hospital, AngersGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
First posted
Nov 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether the administration of a low dose of tranexamic acid just after vaginal delivery can reduce the incidence of immediate postpartum hemorrhage, in women who receive a prophylactic administration of oxytocin.

Conditions

  • Immediate Postpartum Hemorrhage

Interventions

  • Tranexamic AcidDrug

    Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin

  • PlaceboDrug

    Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of PPHTime frame: 24 hours after birth

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Angers University Hospital

    Angers, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.